Navigation Links
Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer

WALTHAM, Mass., March 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010. Based on clinical data and expert opinion, Herceptin plus chemotherapy has competitive advantages in efficacy relative to other current therapies, and it has shown to significantly improve median overall survival compared with chemotherapy alone.

"Despite the recent approval of Herceptin—the first targeted agent approved for gastric cancer—only HER2-positive patients will be eligible for it. Therefore there is still a very high unmet need for further targeted agents that extend survival of patients," stated Decision Resources Analyst Rachel Webster, Ph.D.

The new report entitled Gastric Cancer (Unresectable): An Emerging Biological Agent Will Take Over as Market Leader in 2013 also finds that a therapy that improves the median overall survival of unresectable gastric cancer patients compared with capecitabine/cisplatin would earn 58 percent patient share in the U.S., according to surveyed U.S. oncologists. In contrast, in Europe, such an agent would earn a lower patient share of 48 percent, according to surveyed European oncologists. The difference in patient share suggests that in Europe, physician prescribing decisions are strongly influenced by reimbursement policies.

"Despite the need for more-efficacious therapies that improve median overall survival and the need for more tolerable therapies that can be used in more patients, reimbursement restrictions in Europe constrain physicians from prescribing novel, premium-priced therapies," added Dr. Webster.

About the Report

Gastric Cancer (Unresectable): An Emerging Biological Agent Will Take Over as Market Leader is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    For more information, contact:
    Decision Resources
    Christopher Comfort

SOURCE Decision Resources

Back to top



SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
2. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
3. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
4. Mathematical modeling predicts response to Herceptin
5. Routine Testing Would Improve Herceptin Use in Breast Cancer
6. Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
7. Herceptin Again Proves Mettle Against Breast Cancer
8. Chemo With Herceptin May Be Best for Some Breast Cancers
9. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
10. Herceptin and Tykerb effective against a subset of gastric cancers
11. Neurotechnologija Releases Smartcard Face-Match Add-on for the Implementation of Biometric Face-on-Smartcard Verification Systems
Post Your Comments:
(Date:11/25/2015)... ... , ... Smiles by Stevens is pleased to announce the addition ... many patients are aware of the benefits of Botox® in the treatment of moderate ... with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) ...
(Date:11/25/2015)... , ... November 25, 2015 , ... “While riding the ... inventor, from Bronx, N.Y. “I thought there had to be a convenient and comfortable ... PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or inclement ...
(Date:11/25/2015)... ... 25, 2015 , ... Privately owned Contract Development and Manufacturing ... its current state of the art research, development and manufacturing facility outside of ... manufacturing capacity as well as to support its clients’ growing research and development ...
(Date:11/25/2015)... Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... in prizes were awarded to winners of the Create Real Impact awards. California ... creative expression to help stem the tide of distracted and reckless driving, the number ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek treatment ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing dental ... dental implants. , Missing teeth can lead to a variety of complications if ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... , Nov. 24, 2015  DILON Diagnostics and ... signed an agreement for DILON to distribute GE,s Discovery ... the globe. The signing of this distribution agreement will provide ... Molecular Breast Imaging system and is considered an initial ... better healthcare solutions for clinicians and their patients. ...
(Date:11/24/2015)... November 24, 2015 ... adds Latest Guidebook for Chinese Medical ... pages published in November 2015 to the medical ... intelligence library at . ... fastest growing global economies with a fifth population ...
Breaking Medicine Technology: